Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025
Oral presentation to highlight 24-week efficacy and safety data
Poster to feature results of AI-based analyses of liver fibrosis reduction
Details of the presentations are as follows:
Poster Presentation Details
- Abstract Title: Reduction of Liver Fibrosis by AI-Based Digital Pathology Analysis: Results from the Pemvidutide Phase 2 IMPACT Trial
- Session: Saturday Late-Breaking Posters (publication number 5025)
- Date/Time: The presenter will present/take questions during Poster Session II on
Saturday, November 8, 2025 from 1:00 –2:00 p.m. ET . The poster will be on display throughout The Liver Meeting® - Presenter: Dr.
Julio Gutierrez , Transplant Hepatologist at the Scripps Organ and Cell Transplant Program and Senior Medical Director at Altimmune
Oral Presentation Details
- Abstract Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
- Session: Late-Breaking Abstracts Parallel Session 3 (publication number 5001)
- Date/Time:
Tuesday, November 11, 2025 at11:45 a.m. ET - Presenter: Dr.
Mazen Noureddin , Professor of Medicine at theHouston Methodist Hospital and Co-Chairman of theBoard for Summit and Pinnacle Clinical Research
The AASLD late-breaking presentations will focus on the recent IMPACT Phase 2b readout of the 24-week data. In addition, Altimmune expects to announce 48-week data in Q4 2025.
A copy of the presentation and poster will be accessible on the Events section of the Altimmune website.
About the Phase 2b IMPACT Study
The IMPACT (NCT05989711) trial enrolled 212 participants with biopsy-confirmed MASH and fibrosis stages F2/F3 with and without diabetes randomized 1:2:2 to receive weekly subcutaneous pemvidutide doses at either 1.2 mg, 1.8 mg, or placebo for 24 weeks. Key efficacy endpoints were MASH resolution without worsening of fibrosis, or fibrosis improvement without worsening of MASH at 24 weeks. Secondary endpoints included weight loss and non-invasive tests of fibrosis. Participants will receive a total of 48 weeks of treatment, and a final readout is anticipated in the fourth quarter of 2025.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based 1:1 GLP-1/glucagon dual receptor agonist in development for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), and Alcohol-Associated Liver Disease (ALD). The combined activation of GLP-1 and glucagon receptors results in appetite suppression, weight loss, and direct effects on the liver, including reductions in liver fat, inflammation and fibrosis. The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, both areas of significant unmet medical need. The 48-week readout from the ongoing IMPACT Phase 2b MASH trial is expected in Q4 2025. Phase 2 trials in
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Real Chemistry
efox@realchemistry.com
This press release was published by a CLEAR® Verified individual.
Source: Altimmune, Inc
